FDA grants accelerated approval to Etcamah (camizestrant) for ESR1-mutated HR+ breast cancer. Learn about this new SERD ...
Moonwalk Biosciences closes $70M Series B to advance adipose-targeted RNAi therapies for obesity and cardiometabolic diseases. Learn more about this ...
Novartis's pelacarsen misses primary endpoint in Phase III trial despite lowering Lp(a). Learn what this means for ...
Intellia Therapeutics secures $400M non-dilutive debt facility with OrbiMed to fund commercial launch of CRISPR gene therapy ...
Dimerix Limited secures AUD 34 million non-dilutive funding for Phase III FSGS trial. Discover how this funding advances ...
Acepodia's ACE723 dual-payload ADC wins FDA clearance for Phase I trial in hepatocellular carcinoma. First clinical entry for ...
Superluminal Medicines secures $60M Series B funding to advance MC4R agonist into Phase I trials for rare genetic obesity.
Innovent Biologics begins Phase I trial of IBI3042, a once-weekly oral GLP-1 agonist. Learn about this breakthrough in oral ...
Soufflé Therapeutics launches Phase I/II trial of SFL-0821, an antibody-siRNA conjugate targeting DUX4 for ...
Medicus Pharma licenses Pfizer's discontinued ADC candidate PF-08046031 for $27M upfront and over $1B in potential milestones ...
Milestone Pharmaceuticals' etripamil nasal spray receives China NMPA clearance for PSVT treatment. First regulatory approval ...
Adicet Bio initiates Phase I/II trial of ADI-212, an allogeneic gamma delta CAR-T therapy for metastatic castration-resistant ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results